Email This Release
Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX(R) (interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
